Clinical Trials

recruiting PHASE3 Respiratory / COPD / Asthma NCT05692180

A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma (DOMINICA)

A study to evaluate the efficacy and safety of benralizumab administered subcutaneously in patients ≥ 6 to < 18 years of age with severe eosinophilic asthma, including a well-documented history…

Sponsor: AstraZeneca

View Trial ClinicalTrials.gov ↗

recruiting PHASE3 Respiratory / COPD / Asthma NCT07309614

A Study Assessing the Effect of Dupilumab on Inducing Clinical Remission in Asthma

This study tests whether an asthma medication called dupilumab can help people achieve complete asthma control (called "remission") when given earlier in their disease, before asthma becomes severe. Currently, most…

Sponsor: Université de Sherbrooke

View Trial ClinicalTrials.gov ↗

recruiting PHASE2 Respiratory / COPD / Asthma NCT06676319

Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma

This is a parallel-group, Phase 2, randomized, double-blind, placebo-controlled, 2-arm study for the treatment of asthma. The purpose of this study is to assess the efficacy, safety, and tolerability of…

Sponsor: Sanofi

View Trial ClinicalTrials.gov ↗

recruiting PHASE1 Respiratory / COPD / Asthma NCT07488897

RIG 101 Trial in Healthy Adults and Adults With Asthma

Nested Phase 1-2 Trial of RIG-101 in Healthy and Asthmatic Participants Assessing Safety, Tolerability and Viral Challenge Efficacy

Sponsor: RIGImmune Inc.

View Trial ClinicalTrials.gov ↗

recruiting PHASE4 Respiratory / COPD / Asthma NCT05097287

Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma

This is an interventional, randomized, parallel group, treatment, Phase 3b/4, double blind, 2-arm study to assess the effect of dupilumab compared to standard of care therapy on preventing or slowing…

Sponsor: Sanofi

View Trial ClinicalTrials.gov ↗

recruiting PHASE3 Respiratory / COPD / Asthma NCT06191315

Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to

This is a parallel, Phase 3, 2-arm study to evaluate the efficacy and long-term safety of dupilumab treatment in children 2 to

Sponsor: Sanofi

View Trial ClinicalTrials.gov ↗

recruiting PHASE3 Respiratory / COPD / Asthma NCT06750289

Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment

This study evaluates the efficacy and safety of benralizumab as an add-on therapy in uncontrolled eosinophilic asthma participants treated with medium-dose ICS-LABA compared to the conventional treatment step of escalation…

Sponsor: AstraZeneca

View Trial ClinicalTrials.gov ↗

recruiting PHASE4 Respiratory / COPD / Asthma NCT06334575

Molecular Signatures Associated With Response to ICS Treatment in Patients With COPD Stratified by Eosinophil Levels

The 3TR-ICS COPD study is an international, multicentre, randomized, parallel, controlled study that will recruit clinically stable former smokers COPD patients (with no exacerbations in the previous 8 weeks) on…

Sponsor: Maria Joyera Rodríguez

View Trial ClinicalTrials.gov ↗

recruiting PHASE3 Respiratory / COPD / Asthma NCT07190209

Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype

This is a parallel, Phase 2b/Phase 3, 3-arm study to investigate the efficacy, safety, and tolerability of subcutaneous (SC) treatment with lunsekimig compared with placebo in adult participants (aged 40…

Sponsor: Sanofi

View Trial ClinicalTrials.gov ↗

recruiting PHASE2 Respiratory / COPD / Asthma NCT06496620

A Study to Evaluate Solrikitug in Participants With COPD (ZION)

A Randomized, Double-blind, Placebo-controlled, Multiple Dose-Ranging Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Solrikitug in Participants with Chronic Obstructive Pulmonary Disease (COPD).

Sponsor: Uniquity One (UNI)

View Trial ClinicalTrials.gov ↗

Join 10,000+ UK Clinicians